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Objective: Previous studies have shown that depressive and anxiety disorders are strongly related to somatic
symptoms, but much is unclear about the speciﬁcity of this association. This study examines the associations
of speciﬁc depressive and anxiety disorders with somatic symptoms, and whether these associations are
independent of comorbid depressive and anxiety disorders.
Methods: Cross-sectional data were derived from The Netherlands Study of Depression and Anxiety (NESDA). A
total of 2008 persons (mean age: 41.6 years, 64.9% women) were included, consisting of 1367 patients with a
past-month DSM-diagnosis (established with the Composite International Diagnostic Interview [CIDI]) of de-
pressive disorder (major depressive disorder, dysthymic disorder) and/or anxiety disorder (generalized anxiety
disorder, social phobia, panic disorder, agoraphobia), and 641 controls. Somatic symptoms were assessed with
the somatization scale of the Four-Dimensional SymptomQuestionnaire (4DSQ), and included cardiopulmonary,
musculoskeletal, gastrointestinal, and general symptoms. Analyses were adjusted for covariates such as chronic
somatic diseases, sociodemographics, and lifestyle factors.
Results: All clusters of somatic symptoms were more prevalent in patients with depressive and/or anxiety
disorders than in controls (all p b .001).Multivariable logistic regression analyses showed that all types of depres-
sive and anxiety disorders were independently related to somatic symptoms, except for dysthymic disorder.
Major depressive disorder showed the strongest associations. Associations remained similar after adjustment
for covariates.
Conclusion: This study demonstrated that depressive and anxiety disorders show strong and partly differential
associations with somatic symptoms. Future research should investigate whether an adequate consideration
and treatment of somatic symptoms in depressed and/or anxious patients improve treatment outcomes.© 2014 Elsevier Inc. All rights reserved.Introduction
Depressive and anxiety disorders are among the most common
mental disorders in the general population [1,2], with 12-month
prevalence rates ranging from 1.8% for panic disorder to 6.9% for
major depressive disorder [3]. The burden of disease is high, as the
disorders affect social, personal, and occupational functioning [4–6],
and constitute a considerable economic burden on society [6,7].
Extensive evidence suggests that depressive and anxiety disorders
are strongly related to somatic symptoms [8–12]. Two pediatric studies,
for example, showed that nearly all somatic symptoms were more
prevalent in patients with a depressive and/or anxiety disorder than
in controls [9,11]. In addition, somatic symptoms have been shown to
be associated with at least a twofold increased risk of having a depres-
sive and/or anxiety disorder [8,12,13]. The co-occurrence of depressivery, University Medical Center
erlands. Tel.: +31 503618085.
schloo@umcg.nl (L. Boschloo),
umcg.nl (R.A. Schoevers).and anxiety disorders with somatic symptoms is associated with more
functional disability, higher medical care utilization, and higher costs
than the pathologies apart [14,15]. Both for clinical and scientiﬁc rea-
sons, it is important to improve our understanding of this association.
Three mechanisms have been hypothesized to explain the associa-
tion of depressive and anxiety disorders with somatic symptoms. First,
in the antecedent hypothesis, depressive and anxiety disorders cause
the onset of somatic symptoms [16–19] via, for example, an increased
awareness and an altered perception of physical sensations [20,21].
Second, according to the consequence hypothesis, somatic symptoms
predict the onset of depressive and anxiety disorders [18,22–25], as,
for example, the bodily inconvenience and physical limitations of so-
matic symptoms might cause symptoms of depression and anxiety
[26,27]. Third, in the common etiology hypothesis, shared etiological
factors (e.g., environmental, psychological, and biological factors) inde-
pendently cause the onset of depressive and anxiety disorders aswell as
somatic symptoms [18,27,28].
Although the co-occurrence of depressive and anxiety disorders
with somatic symptoms has often been reported, little is known about
the speciﬁcity of this association. For example, it is unclear whether
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der. In addition, previous studies have speculated that depressive disor-
ders may be more strongly associated with pain symptoms such as
musculoskeletal symptoms [29,30], whereas anxiety disorders might
show stronger associations with cardiopulmonary symptoms [12,31].
Developing a better understanding of the speciﬁcity of the association
may provide important insights into its etiology, and could be of help
in developing therapies for patients with depressive and/or anxiety
disorders as well as somatic symptoms.
Previous studies examining the speciﬁcity of associations have an im-
portant limitation, as they have often not considered the comorbidity of
different depressive and anxiety disorders [13,32]. This is problematic,
since depressive and anxiety disorders often co-occur [33,34], and, as a
consequence of the confounding effects of comorbid disorders, previous
studies could incorrectly have reported similar associations across
speciﬁc depressive and anxiety disorders. In addition, it would be
important to take into account the effects of covariates [13,29,35]. As
depressive and anxiety disorders are associated with somatic diseases
[36], and somatic symptoms are often consequences of somatic diseases
[13], it is essential to get insight into the effects of these diseases by
adjusting for their presence. Similarly, it would be important to take
into account the effects of sociodemographics and lifestyle factors, as
these factors have shown associations with the presence of depressive
and anxiety disorders [37] and somatic symptoms [13,38,39].
The present study focuses on the associations of speciﬁc depressive
and anxiety disorders with somatic symptoms by using a large dataset
of patients with DSM-IV depressive and/or anxiety disorders (N =
1367) as well as healthy controls (N= 641). The aims of this study are:
a. To examine the associations of speciﬁc depressive disorders
(i.e., major depressive disorder and dysthymic disorder) and anxiety
disorders (i.e., generalized anxiety disorder, social phobia, panic dis-
order, and agoraphobia) with different clusters of somatic symp-
toms;
b. To determinewhether these associations are independent of comor-
bid depressive and anxiety disorders;
c. To determine whether these associations can be explained by the
potentially confounding effects of chronic somatic diseases,
sociodemographics, and lifestyle factors.
Methods
Study sample
Data were derived from the baseline measurements of The
Netherlands Study of Depression and Anxiety (NESDA), an ongoing
cohort study aimed at examining the development and long-term prog-
nosis of depressive and anxiety disorders among adults (18–65 years).
For the baseline assessment, 2981 persons were included, consisting
of healthy controls (N = 625, 22%), persons with a current (past-
month) depressive and/or anxiety disorder (N = 1411, 47%), and per-
sons with a prior history of a depressive and/or anxiety disorder
(N=918, 31%). To represent various settings and developmental stages
of psychopathology, recruitment took place in the community (19%),
primary care (54%), and specializedmental health care (27%). Exclusion
criteria were a primary clinical diagnosis of psychotic disorder, obses-
sive–compulsive disorder, bipolar disorder or severe substance use dis-
order, and insufﬁcient command of the Dutch language. The baseline
assessment consisted of an extended face-to-face interview, including
a standardized diagnostic psychiatric interview, as well as paper-and-
pencil questionnaires. The research protocol was approved by the
Ethical Committee of the three participating universities, and all partic-
ipants gave written informed consent. A detailed description of the
NESDA study design can be found elsewhere [40].
For the present study, we selected both healthy controls without a
lifetime depressive or anxiety disorder (N = 652), and patients with acurrent (past-month) depressive and/or anxiety disorder (N = 1411).
Participants with missing data on somatic symptoms (N = 55, 2.7%)
were excluded, resulting in a total sample of 2008 persons. Persons
with valid data on somatic symptomswere less likely to have an anxiety
disorder (p= .04) compared to non-responders, whereas age (p= .75),
gender (p = .67), education (p = .60), and depressive disorder (p =
.17) were not associated with non-response.
Depressive and anxiety disorders
Lifetime and current diagnoses of depressive and anxiety disorders
were establishedwith theComposite International Diagnostic Interview
(CIDI) [41], version 2.1. The CIDI is a reliable instrument, which classiﬁes
diagnoses according to the DSM-IV criteria [42], and was administered
by specially trained research staff. The following types of disorders
were distinguished: major depressive disorder, dysthymic disorder,
generalized anxiety disorder, social phobia, panic disorder, and
agoraphobia.
Somatic symptoms
The presence of somatic symptoms was measured with the somati-
zation scale of the Four-Dimensional Symptom Questionnaire (4DSQ)
[43]. This scale assesses the frequency of experiencing 16 somatic
symptoms in the past week (scores ranging from 1 = never to 5 =
very often or constantly). Based on previous studies [30,44], four clus-
ters of somatic symptoms were distinguished: cardiopulmonary symp-
toms (i.e., excessive perspiration, pain in chest, palpitations, pressure or
tight feeling in chest, shortness of breath), musculoskeletal symptoms
(i.e., back pain, neck pain, muscle pain, tingling in ﬁngers), gastrointes-
tinal symptoms (i.e., bloated feeling in abdomen, nausea or upset stom-
ach, pain in abdomen or stomach area), and general symptoms
(i.e., dizziness or feeling lightheaded, fainting, headache). The symptom
‘blurred vision or spots in front of your eyes’was excluded, since it did
not ﬁt the clusters of somatic symptoms [44]. A speciﬁc cluster of
somatic symptoms was considered present when at least one of its
symptomswas experienced regularly or more often (score 3 or higher).
Covariates
Analyses were adjusted for the potential effects of chronic somatic
diseases, sociodemographics and lifestyle factors. First of all, the number
of self-reported chronic diseases for which persons received treatment
was considered. For the assessment, participants were asked whether
they had speciﬁc diseases (i.e., lung disease, heart disease, diabetes
mellitus, CVA, arthritis, osteoarthritis, rheumatic complaints, tumor, hy-
pertension, gastrointestinal ulcer or disorder, liver disease, epilepsy,
chronic fatigue syndrome, allergy, thyroid gland disease, injury) or po-
tential additional chronic somatic diseases that were not explicitly
asked, and whether they received treatment for the reported diseases.
Sociodemographics included age (in years), gender, education (in
years), partner status (partner versus no partner), and working status
(employed versus unemployed). Lifestyle factors included smoking
status (never, former, current; assessed by self-report), alcohol use (de-
ﬁned as the total score on the Alcohol Use Disorders Identiﬁcation Test
[45]), and physical activity (measured with the International Physical
Activity Questionnaire in MET-minutes [ratio of energy expenditure
during activity compared with rest times the number of minutes
performing the activity] a week [46]).
Statistical analyses
Analyseswere conducted using SPSS version 20.0 (SPSS Inc, Chicago,
Illinois). Characteristics of the study samplewere summarized using de-
scriptive statistics. Subsequently,χ2 analyses were used to compare the
prevalence of all clusters of somatic symptoms in patients with any
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er associations with somatic symptoms were conditional on the type of
depressive or anxiety disorder, χ2 analyses were performed for all spe-
ciﬁc depressive and anxiety disorders separately versus healthy controls
(i.e., separatemodels formajor depressive disorder, dysthymic disorder,
generalized anxiety disorder, social phobia, panic disorder, and agora-
phobia versus healthy controls). Crosstabs were used to describe co-
morbidity patterns between speciﬁc depressive and anxiety disorders.
To determine whether speciﬁc depressive and anxiety disorders
showed independent associations with somatic symptoms, multivari-
able logistic regression analyses were performed including all types of
depressive and anxiety disorders as independent variables in a single
model. Differences in odds ratios were considered signiﬁcant when the
odds ratio of one association showed no overlapwith the 95% conﬁdence
interval of the other association, and vice versa. To get insight in the po-
tential effects of multicollinearity, variance inﬂation factors (VIFs) were
calculated for all depressive and anxiety disorders. Finally, analyses
were adjusted for chronic somatic diseases, sociodemographics, and life-
style factors.
Results
Sample
The characteristics of our sample (N = 2008) are presented in Table 1. Of the whole
sample, 641 (32%) persons were healthy controls, and 1367 (68%) persons had a current
depressive and/or anxiety disorder. Mean age was 41.6 years (SD = 13.1), and 64.9%
werewomen. The prevalence of somatic symptoms ranged from35.1% for gastrointestinal
symptoms to 55.2% for musculoskeletal symptoms.
Associations of depressive and anxiety disorders with somatic symptoms
Fig. 1 summarizes the prevalence of all clusters of somatic symptoms in healthy con-
trols, and patients with depressive and anxiety disorders. The prevalence of all clusters ofTable 1
Sample characteristics (N = 2008).
N (%)/mean (SD)a
Sociodemographics
Age in years 41.6 (13.1)
Female gender 1303 (64.9%)
Education in years 12.0 (3.3)
Having a partner 1368 (68.1%)
Being employed 1146 (57.1%)
Lifestyle factors
Smoking status
Never 586 (29.2%)
Former 647 (32.2%)
Current 775 (38.6%)
Alcohol usage (score AUDIT questionnaire) 4.8 (4.8)
Physical activity (in 1,000 MET-minutes/week) 3.6 (3.1)
Chronic somatic diseases
Number of chronic somatic diseases 0.6 (0.9)
Depressive and/or anxiety disorder
Any depressive and/or anxiety disorder (general)
Absent 641 (31.9%)
Present 1367 (68.1%)
Type of depressive or anxiety disorder
Major depressive disorder 775 (38.6%)
Dysthymic disorder 272 (13.5%)
Generalized anxiety disorder 378 (18.8%)
Social phobia 539 (26.8%)
Panic disorder 495 (24.7%)
Agoraphobia 498 (24.8%)
Cluster of somatic symptoms
Cardiopulmonary symptoms 842 (41.9%)
Musculoskeletal symptoms 1108 (55.2%)
Gastrointestinal symptoms 705 (35.1%)
General symptoms 751 (37.4%)
a Based on descriptive statistics.somatic symptoms was signiﬁcantly (all p b .001) higher in patients with any depressive
and anxiety disorder than in healthy controls (e.g., gastrointestinal symptoms: 45.6% ver-
sus 12.6%; musculoskeletal symptoms: 66.0% versus 32.1%). The same pattern of results
was found for all types of depressive and anxiety disorders, suggesting that associations
were similar across speciﬁc disorders.
Independent associations of depressive and anxiety disorders with somatic symptoms
Table 2 shows the comorbidity rates between speciﬁc depressive and anxiety disor-
ders. Comorbidity rates ranged from 18.7% for comorbid dysthymic disorder in agorapho-
bic patients to 82.0% for comorbid major depressive disorder in dysthymic patients. As
comorbidity rateswere high, we examinedwhether speciﬁc depressive and anxiety disor-
ders showed independent associations with somatic symptoms by performing multivari-
able logistic regression analyses including all types of depressive and anxiety disorders as
independent variables in a single model (see Table 3). Variance inﬂation factor (VIF)
values for all depressive and anxiety disorders were between 1.10 and 1.62, indicating
that themodel was unlikely to be affected by highmulticollinearity. Major depressive dis-
order consistently showed strong and signiﬁcant associations with all clusters of somatic
symptoms. In addition, generalized anxiety disorder, social phobia, and panic disorder
were also signiﬁcantly associated with all clusters of somatic symptoms (all p ≤ .01),
while agoraphobia was signiﬁcantly related to cardiopulmonary, musculoskeletal, and
general symptoms but not gastrointestinal symptoms. Dysthymic disorderwasnot related
to any cluster of somatic symptoms. The associations of major depressive disorder were
stronger than associations of all other speciﬁc depressive and anxiety disorders. In general,
associationswere similar for all clusters of somatic symptoms. However, generalized anx-
iety disorder was more strongly related to cardiopulmonary symptoms (OR = 2.12, 95%
CI = 1.64–2.74) than to gastrointestinal symptoms (OR = 1.61, 95% CI = 1.25–2.07).
Impact of covariates
Subsequently, we examined whether associations of speciﬁc depressive and anxiety
disorders with somatic symptoms could be explained by the effects of covariates (see
Table 3). Adjustment for chronic somatic diseases did not substantially change results. In
addition, associations generally remained similar after additional adjustment for
sociodemographics and lifestyle factors. However, odds ratios slightly decreased, and, con-
sequently, the association between agoraphobia and musculoskeletal symptoms lost sig-
niﬁcance (OR = 1.42, p = .02 decreased to OR = 1.29, p = .09), whereas dysthymic
disorder became signiﬁcantly associated with gastrointestinal symptoms (OR = 1.32,
p = .07 increased to OR = 1.39, p = .04).
Discussion
The present study showed that all depressive and anxiety disor-
ders, except for dysthymic disorder, were independently associated
with all clusters of somatic symptoms. In general, associations were
similar across speciﬁc depressive and anxiety disorders, although
major depressive disorder showed the strongest associations with all
somatic symptom clusters. Adjustment for chronic somatic diseases,
sociodemographics, and lifestyle factors did not substantially change
results.
This study has both strengths and limitations. To our knowledge, this
is the ﬁrst study to examine independent associations of depressive and
anxiety disorders with different clusters of somatic symptoms. The im-
portance of taking into account comorbid depressive and anxiety disor-
ders has been demonstrated clearly in this study, as the comorbidity
across disorders was high (i.e.,18.7%–82.0%), and the associations dif-
fered signiﬁcantly between disorders. Another strength is the large
sample of 2008 persons, consisting of patients with speciﬁc types of de-
pressive and anxiety disorders (N = 1367) and controls (N = 641). In
addition, psychiatric diagnoses were established with a well validated
psychiatric interview among all participants. When interpreting our re-
sults, it is also important to keep some limitations in mind. First, as the
recruitment of patients with depressive and anxiety disorders largely
took place in primary care and specialized mental health care, patients
from our sample may have had more severe psychiatric problems,
and, consequently, more co-occurring somatic symptoms than patients
from the community. Therefore, our results cannot be generalized to the
general population. Another limitation is that we dichotomized data on
somatic symptoms, and we only considered self-rated somatic symp-
toms in the past week. Furthermore, participants were not asked to
grade the severity of their somatic symptoms, so even mild symptoms
with limited clinical signiﬁcancemay have been reported. However, ex-
cluding such mild symptoms from analyses would probably not have
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Fig. 1. Prevalence of clusters of somatic symptoms across controls and patients with a depressive and/or anxiety disorder.
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anxiety disorders with somatic symptoms, since persons with depres-
sive and anxiety disorders have a tendency to report more severe so-
matic symptoms than persons without these disorders [8]. In addition,
the assessment of covariates was based on self-report only, which
could have affected data on somatic diseases and lifestyle factors, as
these factorsmay be inﬂuenced by recall bias and reporting bias, respec-
tively. Furthermore, as the assessment of somatic diseases included only
somatic diseases with a chronic course, the effects of acute somatic dis-
eases (e.g., acute respiratory tract or gastrointestinal infections) were
not taken into account. Still, it is highly unlikely that the found associa-
tions between depressive and anxiety disorders and somatic symptoms
were based on the presence of somatic diseases, as the self-report of
somatic diseases has shown to be accurate [47], and the number of
somatic symptoms reported in this study was substantially higher
than could be explained by somatic diseases alone.
The association between depressive and anxiety disorders with
somatic symptoms has been reported by a number of previous stud-
ies [13–17,19,29,48,49]. However, these studies have shown mixed
results regarding the speciﬁcity of associations. For example,
Means-Christensen et al. [29] demonstrated that major depressive
disorder was associated with more types of pain symptoms than
generalized anxiety disorder, panic disorder, and social phobia,
whereas other studies mainly reported similar symptom counts
across all speciﬁc depressive and anxiety disorders [13,32]. As
these studies often did not take into account the effects of comorbid
depressive and anxiety disorders, one possible explanation for these
inconsistencies might be the different comorbidity rates across studies.Table 2
Comorbidity across speciﬁc depressive and anxiety disorders.
Comorbid disorder
Major depressive disorder Dysthymic disord
Major depressive disorder (N = 775) — 28.8%
Dysthymic disorder (N = 272) 82.0% –
Generalized anxiety disorder (N = 378) 64.0% 32.0%
Social phobia (N = 539) 46.6% 22.1%
Panic disorder (N = 495) 47.7% 20.0%
Agoraphobia (N = 498) 43.0% 18.7%The independent associations of speciﬁc depressive and anxiety
disorders with speciﬁc types of somatic symptoms have, to the best of
our knowledge, so far not been described in the literature. The only
exception to this is the study by Beesdo et al. [35], who have examined
independent associations of speciﬁc depressive and anxiety disorders
with pain, and showed, consistentwith our study, that nearly all speciﬁc
depressive and anxiety disorders were independently associated with
functional (medically insufﬁciently explained) pain symptoms. Howev-
er, contrary to our results, a signiﬁcant association of dysthymic disor-
der with functional pain, and a non-signiﬁcant relation of social
phobia and agoraphobia with functional pain were found. These incon-
sistencies may be explained by different deﬁnitions of depressive and
anxiety disorders as well as somatic symptoms. As Beesdo et al. [35]
assessed depressive and anxiety disorders during the past 12 months,
in contrast to the one-month diagnoses in the current study, this
could, for example, have resulted in differences in the severity of psy-
chopathology across our studies. Furthermore, Beesdo et al. [35] consid-
ered lifetime pain symptoms, which are associatedwith recall bias, and,
consequently, are less reliable and consistent than symptoms in the past
week, as suggested by previous research [50,51].
Several explanations for our results should be discussed. First, the
association between depressive and anxiety disorders and somatic
symptoms could have resulted from symptom overlap; that is, diag-
nostic criteria for depressive and anxiety disorders include somatic
symptoms (e.g., cardiopulmonary symptoms are criteria for panic
disorder) [42]. However, as non-overlapping somatic symptoms
also showed strong associations with depressive and anxiety disor-
ders, the association between depressive and anxiety disorders ander Generalized anxiety disorder Social phobia Panic disorder Agoraphobia
31.2% 32.4% 30.5% 27.6%
44.5% 43.8% 36.4% 34.2%
– 41.8% 36.5% 36.5%
29.3% – 41.0% 40.1%
27.9% 44.6% – 70.5%
27.7% 43.4% 70.1% –
Table 3
Independent associations of speciﬁc depressive and anxiety disorders with clusters of somatic symptoms.
Depressive or anxiety disorder Cardiopulmonary symptoms Musculoskeletal symptoms Gastrointestinal symptoms General symptoms
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Adjusted for all types of depressive and anxiety disordersa
Major depressive disorder 2.74 2.22–3.38 b .001 2.69 2.18–3.32 b .001 2.63 2.13–3.24 b .001 2.93 2.37–3.62 b .001
Dysthymic disorder 1.14 0.84–1.55 .39 1.33 0.96–1.85 .09 1.33 0.99–1.79 .06 1.20 0.89–1.62 .23
Generalized anxiety disorder 2.12 1.64–2.74 b .001 1.99 1.51–2.61 b .001 1.61 1.25–2.07 b .001 1.68 1.31–2.17 b .001
Social phobia 1.67 1.33–2.08 b .001 1.42 1.13–1.77 .003 1.65 1.32–2.06 b .001 1.58 1.26–1.97 b .001
Panic disorder 1.80 1.37–2.38 b .001 1.45 1.09–1.93 .01 1.64 1.24–2.16 b .001 1.91 1.45–2.52 b .001
Agoraphobia 1.56 1.18–2.06 .002 1.57 1.19–2.08 .002 1.28 0.97–1.68 .09 1.47 1.12–1.94 .006
Additionally adjusted for chronic somatic diseasesb
Major depressive disorder 2.65 2.15–3.28 b .001 2.60 2.09–3.22 b .001 2.54 2.06–3.14 b .001 2.86 2.32–3.54 b .001
Dysthymic disorder 1.12 0.83–1.53 .46 1.32 0.95–1.84 .10 1.32 0.98–1.77 .07 1.19 0.88–1.60 .26
Generalized anxiety disorder 2.08 1.60–2.70 b .001 1.93 1.46–2.55 b .001 1.58 1.22–2.03 b .001 1.66 1.29–2.14 b .001
Social phobia 1.70 1.36–2.13 b .001 1.44 1.14–1.81 .002 1.68 1.34–2.10 b .001 1.59 1.27–1.99 b .001
Panic disorder 1.88 1.42–2.49 b .001 1.53 1.15–2.05 .004 1.69 1.28–2.24 b .001 1.95 1.48–2.58 b .001
Agoraphobia 1.44 1.09–1.91 .01 1.42 1.06–1.89 .02 1.19 0.90–1.57 .24 1.41 1.07–1.87 .02
Additionally adjusted for sociodemographics and lifestyle factorsc
Major depressive disorder 2.53 2.04–3.14 b .001 2.42 1.94–3.02 b .001 2.34 1.88–2.91 b .001 2.66 2.14–3.30 b .001
Dysthymic disorder 1.09 0.80–1.49 .60 1.30 0.93–1.83 .13 1.39 1.02–1.88 .04 1.25 0.92–1.70 .16
Generalized anxiety disorder 2.05 1.58–2.67 b .001 1.90 1.43–2.52 b .001 1.58 1.22–2.04 .001 1.65 1.28–2.14 b .001
Social phobia 1.66 1.32–2.08 b .001 1.41 1.12–1.78 .004 1.62 1.29–2.04 b .001 1.56 1.24–1.96 b .001
Panic disorder 1.83 1.38–2.42 b .001 1.44 1.07–1.93 .02 1.56 1.17–2.08 .002 1.82 1.37–2.41 b .001
Agoraphobia 1.38 1.04–1.83 .03 1.29 0.96–1.73 .09 1.13 0.85–1.51 .39 1.34 1.01–1.79 .04
a Based on multivariable logistic regression analyses including all types of depressive and anxiety disorders.
b Based on multivariable logistic regression analyses including all types of depressive and anxiety disorders and chronic somatic diseases.
c Based on multivariable logistic regression analyses including all types of depressive and anxiety disorders, chronic somatic diseases, age, gender, education, partner status, working
status, smoking status, alcohol usage, and physical activity.
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symptoms.
In addition, this study found that depressive and anxiety disorders
generally showed similar associations with somatic symptoms, al-
though some differences were observed. Major depressive disorder
showed the strongest associations, while all anxiety disorders showed
moderate associations, and dysthymic disorder was not related to so-
matic symptoms. These differences in associations might be explained
by variance in the severity of psychopathology [11]. For example, in
the antecedent hypothesis, more severe depressive and anxiety disor-
ders may cause more somatic symptoms, whereas in the consequence
hypothesis, more somatic symptoms might cause more severe depres-
sion and/or anxiety. In the current study, the severity of psychopathol-
ogy may have differed across speciﬁc depressive and anxiety
disorders, as, for example, a diagnosis of major depressive disorder re-
quires more and more frequent symptoms than a diagnosis of dysthy-
mic disorder [42]. Although the severity of psychopathology of speciﬁc
depressive and anxiety disorders is difﬁcult to compare, a previous
study showed that current major depressive disorder was associated
with higher functional impairment than current generalized anxiety
disorder, social phobia, panic disorder, and agoraphobia [52], indicating
that psychopathology of major depressive disorder might be more se-
vere than psychopathology of all anxiety disorders. However, as the
mentioned study did not examine dysthymic disorder, we are not able
to draw conclusions about this explanation.
A second hypothesis concerning the speciﬁcity of associations, is
whether depressive disorders show differential associations with spe-
ciﬁc clusters of somatic symptoms than anxiety disorders. Our results
showed that associations with depressive and anxiety disorders were
similar across speciﬁc clusters of somatic symptoms, suggesting that de-
pressive and anxiety disorders are not differentially associated with
speciﬁc types of somatic symptoms. However, it is important to note
that wewere not able to take into account the co-occurrence of somatic
symptom clusters. In our sample, the percentage of persons reporting
only one cluster of somatic symptoms ranged from 7.6% for those
reporting general symptoms to 19.5% for those reportingmusculoskele-
tal symptoms. Future studies should include more persons with onlyone somatic symptom cluster, which would enable them to explicitly
consider associations independent of co-occurring somatic symptoms.
Another issue that should be discussed is the origin of somatic symp-
toms in this study. Somatic symptoms can be consequences of organic
pathology, but previous studies have shown that up to two thirds of so-
matic symptoms could not be fully explained by amedical condition [13,
53]. These functional somatic symptoms are strongly associated with
both depressive and anxiety disorders [12,27]. As the somatization
scale of the 4DSQ is a proper indicator of the general practitioner's sus-
picion of somatization [43], and the prevalence of somatic symptoms in
our study was substantially higher than can be explained by medical
conditions, we suggest that a major proportion of the somatic symp-
toms reported in the current study are indeed functional somatic symp-
toms. Consequently, we suggest that functional somatic symptoms had
an important role in the associations of depressive and anxiety disorders
with somatic symptoms.
Previous studies have shown that somatic symptoms are associated
with an unfavorable course of depressive and anxiety disorders [54–57].
An adequate consideration and treatment of somatic symptoms in pa-
tients with depressive and anxiety disorders might therefore improve
the outcome of these patients. Validated screening instruments are
available for a systematic assessment of somatic symptoms [58]. In ad-
dition, several treatment options such as cognitive behavioral therapy
[59,60] andmindfulness [61–63] have shown to be effective for depres-
sive and anxiety disorders as well as somatic symptoms. Future studies
should examine whether systematic screening for somatic symptoms
and treatment of these symptoms in patients with depressive and anx-
iety disorders results in better treatment outcomes and reduced health
care utilization and costs.
Conclusions
Depressive and anxiety disorders are strongly related to somatic
symptoms and these associations show some differences across speciﬁc
depressive and anxiety disorders. Further research is needed to examine
potential explanations for the variation in independent associations
across speciﬁc depressive and anxiety disorders as well as to study
121E. Bekhuis et al. / Journal of Psychosomatic Research 78 (2015) 116–122whether an adequate consideration of somatic symptoms in patients
with depressive and anxiety disorders improves treatment outcomes.
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